OA13013A - Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. - Google Patents

Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. Download PDF

Info

Publication number: OA13013A
Authority: OA; OAPI
Prior art keywords: degrees; expressed; strontium ranelate; strokes; crystalline form
Prior art date: 2004-09-30

Application number

OA1200500169A

Other languages

English (en)

French (fr)

Inventor

Stephane Horvath

Isabelle Demuynck

Gerard Damien

Original Assignee

Laboratiores Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-06-02

Publication date

2006-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA13013(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-02 Application filed by Laboratiores Servier filed Critical Laboratiores Servier

2006-11-10 Publication of OA13013A publication Critical patent/OA13013A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Physical Education & Sports Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Steroid Compounds (AREA)
Fodder In General (AREA)

OA1200500169A 2004-09-30 2005-06-02 Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent. OA13013A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0410335A FR2875807B1 (fr)	2004-09-30	2004-09-30	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number	Publication Date
OA13013A true OA13013A (fr)	2006-11-10

Family

ID=34942420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500169A OA13013A (fr)	2004-09-30	2005-06-02	Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent.

Country Status (42)

Country	Link
US (2)	US7459568B2 (es)
EP (2)	EP1642897B9 (es)
JP (2)	JP2006104184A (es)
KR (1)	KR100816590B1 (es)
CN (1)	CN100391956C (es)
AP (1)	AP1930A (es)
AR (1)	AR049395A1 (es)
AT (1)	ATE411308T1 (es)
AU (1)	AU2005202718B2 (es)
BR (1)	BRPI0502228A (es)
CA (1)	CA2508824C (es)
CO (1)	CO5710195A1 (es)
CR (1)	CR7876A (es)
CY (1)	CY1108797T1 (es)
DE (1)	DE602005010359D1 (es)
DK (1)	DK1642897T3 (es)
EA (1)	EA008474B1 (es)
EC (1)	ECSP055859A (es)
ES (1)	ES2314593T3 (es)
FR (1)	FR2875807B1 (es)
GE (1)	GEP20074106B (es)
GT (1)	GT200500130A (es)
HK (1)	HK1086260A1 (es)
HR (1)	HRP20080652T3 (es)
IL (1)	IL169237A (es)
MA (1)	MA27815A1 (es)
MX (1)	MXPA05006407A (es)
NO (1)	NO333948B1 (es)
NZ (1)	NZ540802A (es)
OA (1)	OA13013A (es)
PA (1)	PA8638201A1 (es)
PE (1)	PE20060364A1 (es)
PL (1)	PL1642897T3 (es)
PT (1)	PT1642897E (es)
RS (1)	RS51110B (es)
SA (1)	SA05260168B1 (es)
SG (1)	SG121035A1 (es)
SI (1)	SI1642897T1 (es)
TW (1)	TWI367881B (es)
UA (1)	UA80008C2 (es)
WO (1)	WO2006035122A1 (es)
ZA (1)	ZA200504937B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292529A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating osteoporotic conditions
US20070292535A1 (en) *	2006-06-19	2007-12-20	Tabbiner Philip S	Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CN101206208B (zh) *	2006-12-19	2011-08-10	北京德众万全药物技术开发有限公司	一种用hplc法分析雷尼酸锶原料及其制剂的方法
WO2010034806A1 (en)	2008-09-29	2010-04-01	Ratiopharm Gmbh	Anhydrate and hydrate forms of strontium ranelate
IT1398542B1 (it) *	2010-03-05	2013-03-01	Chemelectiva S R L	Processo per la preparazione di un polimorfo
CN102241663B (zh) *	2010-05-10	2013-02-13	山东方明药业集团股份有限公司	一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) *	2011-04-21	2012-10-26	Shilpa Medicare Limited	Crystalline strontium ranelate form-s
CZ2011320A3 (cs)	2011-05-30	2012-12-12	Zentiva, K.S.	Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en)	2011-05-31	2012-12-05	Lacer, S.A.	New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en)	2011-07-21	2013-01-24	Emory University	Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) *	2011-09-20	2012-06-20	浙江华海药业股份有限公司	一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) *	2012-01-31	2013-08-08	Pharmathen S.A.	Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en)	2012-03-23	2013-09-25	Urquima S.A.	Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en)	2012-05-17	2013-10-29	Divi's Laboratories, Ltd.	Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2651497B1 (fr) *	1989-09-01	1991-10-25	Adir	Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl)	1994-07-22	2001-07-31	Lilly Co Eli	Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) *	1996-06-17	1999-11-26	Adir	Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
US7227033B2 (en) *	2002-01-09	2007-06-05	Emisphere Technologies, Inc.	Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
ES2272781T5 (es) *	2001-10-03	2010-04-06	Teva Pharmaceutical Industries Ltd.	Preparacion de levofloxacino hemihidratado.
AU2003258109A1 (en) *	2002-08-06	2004-02-23	Teva Pharmaceutical Industries Ltd.	Novel crystalline forms of gatifloxacin
FR2844795B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) *	2002-09-24	2004-03-26	Servier Lab	Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844797B1 (fr) *	2002-09-24	2004-10-22	Servier Lab	Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) *	2004-09-30	2006-11-17	Servier Lab	Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr active Application Filing
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de active Active
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es active Active
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active IP Right Cessation
2006
- 2006-05-29 HK HK06106187A patent/HK1086260A1/xx not_active IP Right Cessation
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending

Also Published As

Publication number	Publication date
PT1642897E (pt)	2008-11-27
AU2005202718A1 (en)	2006-04-13
US20060069271A1 (en)	2006-03-30
CN1754878A (zh)	2006-04-05
MXPA05006407A (es)	2006-04-05
SA05260168B1 (ar)	2009-02-25
EP1642897B1 (fr)	2008-10-15
RS51110B (sr)	2010-10-31
ATE411308T1 (de)	2008-10-15
CA2508824A1 (fr)	2006-03-30
CN100391956C (zh)	2008-06-04
GEP20074106B (en)	2007-05-10
GT200500130A (es)	2005-12-20
JP2006104184A (ja)	2006-04-20
DE602005010359D1 (de)	2008-11-27
KR20060049966A (ko)	2006-05-19
US7459568B2 (en)	2008-12-02
ECSP055859A (es)	2006-09-18
CO5710195A1 (es)	2006-12-29
FR2875807B1 (fr)	2006-11-17
PE20060364A1 (es)	2006-06-17
US7745482B2 (en)	2010-06-29
SG121035A1 (en)	2006-04-26
EA200500842A1 (ru)	2006-04-28
AR049395A1 (es)	2006-07-26
FR2875807A1 (fr)	2006-03-31
AU2005202718B2 (en)	2010-09-16
NO333948B1 (no)	2013-10-28
EP1642897B9 (fr)	2009-08-12
CA2508824C (fr)	2009-03-24
BRPI0502228A (pt)	2006-05-09
TW200610758A (en)	2006-04-01
AP1930A (en)	2008-12-15
TWI367881B (en)	2012-07-11
PA8638201A1 (es)	2006-05-16
UA80008C2 (uk)	2007-08-10
ES2314593T3 (es)	2009-03-16
PL1642897T3 (pl)	2009-04-30
CR7876A (es)	2007-12-10
AP2005003323A0 (en)	2005-06-30
CY1108797T1 (el)	2014-04-09
IL169237A (en)	2010-12-30
EA008474B1 (ru)	2007-06-29
KR100816590B1 (ko)	2008-03-24
NO20052998D0 (no)	2005-06-17
JP2010132669A (ja)	2010-06-17
US20080312314A1 (en)	2008-12-18
NZ540802A (en)	2006-11-30
NO20052998L (no)	2006-03-31
EP1944302A1 (fr)	2008-07-16
ZA200504937B (en)	2006-04-26
MA27815A1 (fr)	2006-04-03
HK1086260A1 (en)	2006-09-15
EP1642897A1 (fr)	2006-04-05
WO2006035122A1 (fr)	2006-04-06
HRP20080652T3 (en)	2009-01-31
SI1642897T1 (sl)	2009-02-28
DK1642897T3 (da)	2009-01-26

Publication	Publication Date	Title
OA13013A (fr)	2006-11-10	Forme cristalline alpha du ranelate de strontium, son procédé de préparation, et les compositions pharmaceutiques qui la contiennent.
CA2537414C (fr)	2010-02-16	Forme cristalline .beta. du chlorhydrate de l'ivrabadine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537404C (fr)	2010-04-13	Forme cristalline .gamma.-d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537400C (fr)	2009-12-15	Forme cristalline .gamma. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2537420C (fr)	2010-03-30	Forme cristalline bd du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2564367C (fr)	2010-05-18	Forme cristalline .delta. du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CA2564369C (fr)	2010-06-15	Forme cristalline .delta.d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP1296947B1 (fr)	2004-02-04	Forme cristalline alpha du sel de tert-butylamine du perindopril
WO2001083439A2 (fr)	2001-11-08	NOUVELLE FORME CRISTALLINE η DU SEL DE TERT-BUTYLAMINE DU PERINDOPRIL, SON PROCEDE DE PREPARATION, ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
WO2001087836A1 (fr)	2001-11-22	Nouvelle forme cristalline $g(b) du sel de tert-butylamine du perindopril, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR3025197B1 (fr)	2019-09-06	Nouveau sel de 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl)phenoxy]ethyl}-1-benzofurane-2-carboxamide, formes cristallines associees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent